Network Insights Methodology Get Access

Novo Nordisk

ORG Health Care / Pharmaceuticals Momentum 10.0ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. NORMALPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Spectral Shift

$65B market cap (Copenhagen-listed), Novo Nordisk manufactures insulin, diabetes, and obesity treatments. Recent signal shows strategic push to expand obesity drug sales beyond North America into Europe and emerging markets.

Active expansion in obesity and diabetes treatment markets; pursuing international market penetration beyond US with GLP-1 receptor agonist portfolio.
-0.58
PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.
10.0
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
1%
ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.
16
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
Connected Entities
FDA China United States India Eli Lilly Canada OpenAI AstraZeneca European Union CEO Americans Bloomberg Wall Street Netflix Investing.com
Watch This Entity
PSI Intelligence
30-Day Trend
2026-04-25 2026-05-25 16 0 Degree Mentions
Signal Decomposition
Attention Cascade
-0.000
Narrative Drift
0.000
Spectral Shift
624.046
Sentiment-Momentum Divergence
0.000
Source Concentration
0.452
Peer Comparison
Not yet ranked. Sector-relative scoring requires at least four entities in the same BICS sector with PSI history; this entity does not yet meet the threshold or sits in a sector with insufficient peers.
Network Analysis
16 Degree Centrality
Ego Network (top connections)
FDA (weight 16.0)China (weight 11.0)United States (weight 10.0)India (weight 8.0)Eli Lilly (weight 8.0)Canada (weight 6.0)OpenAI (weight 4.0)AstraZeneca (weight 3.0) FDAChinaUnited StatesIndiaEli LillyCanadaOpenAIAstraZeneca Novo Nordisk (degree 16) Novo Nordisk
Centrality History
2026-04-25 2026-05-25 16 0 Degree Mentions
EntityWeight StatusFirst Seen
FDA 16 NEW
China 11 NEW
United States 10 NEW
India 8 NEW
Eli Lilly 8 NEW
Canada 6 NEW
OpenAI 4 NEW
AstraZeneca 3 NEW
European Union 3 NEW
CEO 2 NEW
Americans 2 NEW
Bloomberg 2 NEW
Wall Street 2 NEW
Netflix 2 NEW
Investing.com 2 NEW
Pfizer 1 NEW
Article Coverage (0)
DateLaneTitle
No Plocamium-authored coverage yet. This entity surfaces in upstream signals (news, filings, trials) but has not yet been a primary subject of a published article. Watch this entity to be alerted when one is published.

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-05-25 ← Intelligence Network